What is the Best Treatment for Schizophrenia?

Is schizophrenia genetic? Yes, genetics plays a major role. Research attributes up to about 80% of the risk of developing schizophrenia to genetic factors. But that number comes with an important qualification: no single gene causes schizophrenia, and genes are not the whole story. Having a relative with the condition raises a person's risk, yet most people with an affected relative never develop it, and most people who do develop schizophrenia have no family history of it at all. Genetic risk is real, but it is not destiny. This article explains what the genetics actually show, what else contributes, the types and early signs, and what it means for families.

Is Schizophrenia Hereditary? What the Genetics Show

Schizophrenia can run in the family, and decades of twin, family, and adoption studies have measured how strongly. Twin studies are especially informative. Because identical twins share nearly all their genes while fraternal twins share about half, comparing how often each type of twin shares a diagnosis lets researchers estimate the genetic contribution. Those studies put the heritability of schizophrenia at roughly 79% to 81%, meaning genetic differences account for a large share of why some people develop it and others do not (Sullivan et al., Archives of General Psychiatry, 2003; Hilker et al., Biological Psychiatry, 2018).

‍

It helps to be clear about what heritability does and does not mean. It describes how much of the variation in risk across a population is linked to genetic differences; it does not mean an individual has an 80% chance of developing the condition, and it does not mean the outcome is fixed at birth. Even in identical twins, when one twin has schizophrenia the other develops it only about half the time, which tells us plainly that genes load the dice but do not determine the roll.

‍

So is schizophrenia genetically inherited in a simple way like eye color? No. It is polygenic, which means many genes are involved rather than one. Thousands of common gene variants each add a tiny amount of risk, and a smaller number of rarer variants carry larger effects. Many of these genes influence how brain cells form connections, called synapses, and how chemical messengers between neurons work. There is no single "schizophrenia gene," and because the genetics are spread across so many variants, schizophrenia does not follow a clear-cut pattern of inheritance the way some conditions do (MedlinePlus, Schizophrenia).

How Family History Affects Risk

Family history is the strongest single predictor of risk. The figures below come from classic family and twin studies, and they are best read as approximate lifetime risks for a population, not as a fixed forecast for any one person.

‍

Family history

Approximate lifetime risk

‍

Put another way, having one first-degree relative (a parent or sibling) with schizophrenia raises an individual's risk roughly eight-fold, and having two first-degree relatives raises it about eleven-fold compared with someone with no family history.

‍

A first-degree relative means a parent, sibling, or child (the family members who share about half of your genes). Second-degree relatives, such as grandparents, aunts, and uncles, share less, which is why the risk from a grandparent with schizophrenia is much closer to the general-population figure.

‍

Those numbers can look frightening, so it is essential to read them alongside two facts that are just as true. First, about four out of five people who develop schizophrenia have no affected first-degree relative. Most cases are what researchers call sporadic, arising without a clear family history. Second, even at the highest end of the table, the majority outcome is not developing the condition. With one affected parent, roughly 85 to 90% of children do not develop schizophrenia, and with both parents affected, the majority still do not. Elevated risk is real. Inevitability is not. If you are reading this table with a specific family member in mind, the most useful takeaway is not a percentage but a plan: know the early signs, and know that early care helps.

What Causes Schizophrenia? Beyond Genetics

If you are asking what causes schizophrenia, the honest answer is that genes and environment work together, shaping brain development over time. No single factor acts alone, and there is no one "cause" that applies to everyone. Two people can arrive at the same diagnosis by very different routes, one carrying more genetic risk, another shaped more by environmental factors. This is part of why schizophrenia looks somewhat different from person to person. Alongside genetic risk, researchers have identified several contributors that may increase the likelihood of developing schizophrenia:

‍

• Prenatal and birth factors: complications during pregnancy or birth, maternal infections, or malnutrition before birth.
• Brain chemistry: differences in neurotransmitter systems, particularly dopamine and glutamate, that affect how brain signals are regulated.
• Brain structure and development: subtle differences in brain structure and in how regions connect to one another.
• Substance use: frequent cannabis use in adolescence, especially in people who already carry higher genetic risk.
• Early-life stress or trauma: severe childhood adversity.
• Immune and inflammatory factors: some research links immune activation during key developmental windows to later risk.

‍

Each of these is associated with increased risk rather than a guaranteed cause. Most people exposed to any one of them never develop schizophrenia. The current understanding is what researchers call a neurodevelopmental model: genetic vulnerability and environmental factors interact over years, subtly shaping how the brain develops long before any symptoms appear. This is why schizophrenia typically emerges in late adolescence or early adulthood, a period of major brain maturation, rather than in childhood. It is the combination of influences across development, not any single element, that determines whether the condition emerges. That also means risk is not static: some environmental contributors, like heavy adolescent cannabis use, are ones a person or family can act on.

Types of Schizophrenia

The way clinicians classify schizophrenia has changed. Before 2013, the condition was divided into five subtypes. The DSM-5, and the current DSM-5-TR, folded those subtypes into a single diagnosis of schizophrenia. The reason for the change was that the old subtypes were not stable over time. A person could shift from one to another, and they did not reliably predict treatment response or outcome. In their place, clinicians now use specifiers, notes that describe features like the course of the illness or the presence of catatonia, to capture a person's particular pattern. The older subtype names still appear in some writing, so they are worth knowing:

‍

• Paranoid: prominent delusions and hallucinations.
• Disorganized (hebephrenic): disorganized thinking and speech, and flattened emotional expression.
• Catatonic: movement disturbances, including immobility or mutism.
• Undifferentiated: features of more than one type.
• Residual: reduced symptoms following a previous episode.

‍

Schizophrenia also sits within a broader schizophrenia spectrum that includes related conditions such as schizoaffective disorder, which combines features of schizophrenia and a mood disorder, and schizophreniform disorder, which involves similar symptoms over a shorter period. A clinician distinguishes between these based on the specific pattern and duration of symptoms.

Early Signs of Schizophrenia

The early signs of schizophrenia usually appear in late adolescence or early adulthood, often slightly later in women than in men. Before a first episode, changes can be gradual and easy to miss, which is exactly why families search for them. Common early signs include:

‍

• Social withdrawal and loss of interest in friends or activities
• A decline in functioning at school or work
• Difficulty concentrating or increasingly disorganized thinking
• Unusual or suspicious thoughts, or a sense that something has changed
• Reduced emotional expression or motivation
• Changes in sleep or personal hygiene

‍

Clinicians sometimes call this gradual early phase the prodrome, a period of subtle changes that can precede a first episode by months or even years. These signs are not proof of schizophrenia; many have other explanations, from depression to ordinary adolescent change, and most people who experience them will not develop schizophrenia. But when several appear together and persist, they are a reason to seek an evaluation rather than to wait and see.

‍

A first episode of psychosis, which can include hallucinations, delusions, or disorganized speech, is a particularly important moment. Research consistently shows that the sooner coordinated care begins after psychosis emerges, the better the long-term outcomes tend to be (NIMH, Schizophrenia). Seeking an evaluation early is not an overreaction; it is one of the few things clearly within a family's control that improves the odds.

What This Means for Families

If schizophrenia is in your family, the worry behind the question is usually personal: does this mean it will happen to me, or to my child? The evidence offers a genuinely reassuring answer. A family history raises risk, but it does not make the condition inevitable, and genetic risk is not the same as genetic destiny.

‍

A few things are worth holding onto. There is no routine genetic test that can predict or diagnose schizophrenia, because the condition involves thousands of genes interacting with the environment; diagnosis is clinical, based on symptoms and history. Direct-to-consumer genetic tests that claim to estimate psychiatric risk cannot tell an individual whether they will develop schizophrenia, and a worrying result from one is not a diagnosis.

‍

What families can do is practical rather than passive: learn the early signs, seek an evaluation promptly if concerns come up rather than waiting, and know that effective treatment exists. Modern care combines medication, therapy, and support to help people manage symptoms and build stable, meaningful lives, and outcomes are best when treatment starts early and stays coordinated. For someone carrying a family history, that is the real source of agency: not the genes they inherited, which no one chooses, but the speed and quality of the care they can reach if it is ever needed.

‍

At Amae Health, schizophrenia is one of the conditions our integrated teams are built to treat. If you are looking for information, our guide to the best treatment for schizophrenia and our care for psychosis and first-episode psychosis explain what evidence-based treatment looks like. You can also explore our full range of treatments or read our resources for patients and families. To ask about an evaluation, reach out to our team.

Frequently Asked Questions

Is schizophrenia genetic or environmental?

Both. Genetics accounts for up to about 80% of risk, but environmental factors such as prenatal complications, early trauma, and heavy cannabis use interact with genes to shape whether the condition develops. Neither genes nor environment alone fully explains it.

‍

If a parent has schizophrenia, will their child get it?

Not necessarily. With one parent affected, a child's lifetime risk is roughly 10 to 15%, which means most children of a parent with schizophrenia do not develop it. The risk is higher than average, but it is far from certain.

‍

Can you have schizophrenia with no family history?

Yes. About four out of five people with schizophrenia have no affected first-degree relative. Genetic risk can come from many small variants that are common in the population, and environmental factors also contribute, so the condition frequently appears without a clear family history.

‍

Is there a genetic test for schizophrenia?

No. There is no routine test that can predict or diagnose schizophrenia. Because the condition involves thousands of genes plus environmental influences, no single test can capture it. Diagnosis is made clinically, based on symptoms and history.

‍

At what age does schizophrenia usually appear?

Typically in late adolescence to early adulthood, and often slightly later in women. Early, subtle signs can appear gradually in the months or years before a first episode of psychosis.

‍

Can schizophrenia be prevented if it runs in my family?

It cannot be reliably prevented, but risk can be lowered and outcomes improved. Avoiding heavy cannabis use, managing stress, and seeking evaluation early if warning signs appear all help, and early intervention is linked to better outcomes. If you or a loved one is struggling, support is available: call or text the 988 Suicide and Crisis Lifeline at 988, anytime.

‍

Citations

1. Sullivan PF, Kendler KS, Neale MC. "Schizophrenia as a Complex Trait: Evidence From a Meta-analysis of Twin Studies." Archives of General Psychiatry, 2003. PubMed 14662550. Tier 1 (peer-reviewed meta-analysis).
2. Hilker R, Helenius D, Fagerlund B, et al. "Heritability of Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register." Biological Psychiatry, 2018. sciencedirect.com. Tier 1 (peer-reviewed).
3. MedlinePlus (National Institutes of Health), "Schizophrenia." medlineplus.gov/genetics/condition/schizophrenia. Tier 2 (U.S. government).
4. National Institute of Mental Health, "Schizophrenia." nimh.nih.gov/health/topics/schizophrenia. Tier 2 (U.S. government).

‍

In a single classroom, two students navigate the same diagnosis, yet they look worlds apart. One boy spins in his chair, shouting out answers and pulling the room’s attention toward him. Across the aisle, a girl stares quietly out the window, her homework forgotten and her mind miles away.

We already know which student will be sent to the counselor first.

Because symptoms are often quieter in girls, boys are diagnosed two to three times more often. In reality, ADHD affects both sexes with nearly equal frequency. This gap reveals a hidden crisis in modern medicine: when we only look for the loudest symptoms, millions of women are left without the support they deserve.

At Amae Health, we specialize in identifying and treating ADHD in women and men by focusing on these subtle distinctions. We understand that an accurate diagnosis requires looking past stereotypes to see how symptoms actually manifest in daily life.

Understanding the nuances of ADHD in women vs. men is about more than just a label. It is the key to selecting the most effective treatment and finally providing the clarity that so many have been waiting for.

Understanding ADHD: Types and Core Symptoms

The Three Types of ADHD

Attention deficit hyperactivity disorder includes three main types, each of which can occur in any person regardless of gender:

• Hyperactive-impulsive type. It is characterized by a constant need to move, an inability to sit still, and impulsive actions that often occur without considering the consequences.
• Inattentive type. Previously known simply as attention deficit disorder, this type of ADHD manifests itself through difficulty concentrating, forgetfulness, and difficulty organizing daily activities.
• Combined type. This type combines symptoms from both of the previous categories and is the most common form of the disorder.

It is essential to understand that anyone can have any ADHD, but male ADHD is more likely to manifest itself through hyperactive-impulsive symptoms that are easily noticeable to others. At the same time, women and girls are more likely to exhibit the inattentive type, whose symptoms are less obvious and often go unnoticed by teachers, parents, and even doctors.

How ADHD Affects Daily Life

ADHD seriously affects all areas of a person's life, creating difficulties at work or school, in personal relationships, and with self-esteem. In the workplace, individuals with this disorder may struggle to meet deadlines, organize tasks, and maintain attention during prolonged meetings.

In relationships, female ADHD can manifest itself through forgetfulness about essential dates, difficulty with household chores, or emotional instability, which creates tension in the family.

Academic performance also suffers, but in different ways for men and women. Boys with ADHD are more likely to receive behavioral remarks and be referred to specialists. Girls, on the other hand, may underachieve for years, with their problems being attributed to laziness or lack of motivation. Self-esteem declines in all individuals, but women often blame themselves for their inability to meet social expectations of organization and order.

ADHD Symptoms by Gender: Key Differences

Male ADHD Symptoms and Presentation

Male ADHD usually manifests itself through external, obvious behavioral symptoms that disrupt order in the classroom or at home. Boys with ADHD often cannot sit still, fidget constantly, get up without permission, and may even run or climb in inappropriate situations.

Impulsivity is expressed through shouting answers, inability to wait for their turn, and frequent interruptions of others during conversations.

Aggressive behavior and outbursts of anger are also more common in male ADHD, especially when the child or adult is frustrated. Boys are more likely to lose things, forget to complete tasks, and engage in risky behavior, including:

• Reckless driving in adolescence and adulthood
• Alcohol and drug abuse as a form of self-medication
• Involvement in fights or other confrontational situations
• Disregard for safety rules in various situations

These external, destructive symptoms of male ADHD attract the attention of adults and lead to earlier diagnosis, but also create negative attitudes toward the child from teachers and peers.

Female ADHD Symptoms and Presentation

Female ADHD manifests itself in a completely different way, through internal, less noticeable symptoms that often go unnoticed by those around them.

Girls and women with ADHD are more likely to "have their heads in the clouds," immersed in dreams or their thoughts. Their workspaces and personal belongings may be disorganized, but they do not disrupt others or create noise.

Perfectionism becomes an attempt to compensate for internal chaos — women with ADHD may spend excessive amounts of time completing tasks, redoing them over and over again. Emotional sensitivity manifests itself through strong reactions to criticism, frequent mood swings, and a tendency toward anxiety or depression. Social behavior is also different — instead of aggression, women with ADHD are more likely to:

• Avoid social situations for fear of doing something wrong
• Feel a constant sense of inadequacy and guilt
• Procrastinate for fear of not being able to do a task perfectly
• Have difficulty making decisions even in simple situations

These internal manifestations of female ADHD are often interpreted as personality traits rather than symptoms of a medical condition, leading to significant delays in diagnosis.

Why Male ADHD is Diagnosed More Often

Historical Bias in ADHD Research

The study of ADHD began with observations of hyperactive boys in the 1960s and 1970s. This laid the groundwork for diagnostic criteria that focus on male manifestations of the disorder. Researchers focused on external, destructive symptoms that interfered with the learning process and required immediate intervention.

For many years, ADHD in women and men was not studied as separate phenomena, which led to the creation of diagnostic tools that better identify male-type symptoms. Even modern assessment scales and tests are primarily based on behavioral manifestations that are more characteristic of boys and men.

Questions such as "Does the child often run or climb in inappropriate situations?" or "Does the child interfere with other children during play?" better describe male behavior patterns. At the same time, female symptoms remain outside the scope of standard diagnostics.

Societal Expectations and Gender Norms

Societal expectations play a huge role in how ADHD symptoms are perceived in different genders. Boys' disruptive behavior quickly attracts the attention of teachers, who refer them to the school psychologist or recommend that their parents seek professional help.

Quiet, dreamy girls often do not cause problems in the classroom, so their symptoms are frequently ignored or attributed to personality traits.

Social stereotypes also influence the perception of male ADHD and female ADHD. Girls are expected to be more organized, obedient, and capable of multitasking. Therefore, when they do not meet these expectations, those around them often consider it laziness or a lack of upbringing. Boys, on the other hand, are "forgiven" for some chaos and impulsiveness as standard male traits, but when these behaviors become excessive, they immediately cause concern.

The Impact of Hormones and Biology

Hormonal differences between men and women significantly influence the onset and course of ADHD throughout life. Estrogen, the primary female sex hormone, plays a vital role in regulating dopamine and norepinephrine, neurotransmitters that are disrupted in ADHD. Fluctuations in estrogen levels during the menstrual cycle can lead to worsening symptoms of female ADHD on certain days of the month.

Pregnancy and the postpartum period present unique challenges for women with ADHD. During pregnancy, many medications used to treat ADHD are contraindicated, and hormonal changes can either improve or worsen symptoms. Menopause is often accompanied by a sharp decline in concentration and memory in women who have never suspected they had ADHD.

Testosterone in men, on the other hand, may have a protective effect, helping to maintain more stable dopamine levels. However, male ADHD can also change with age — many men report that hyperactivity decreases into adulthood, but attention and organization problems remain.

Diagnosis and Treatment at Amae Health

At Amae Health, we have developed a specialized approach to ADHD diagnosis that takes into account the differences in symptom presentation between men and women. Our team of experts understands that ADHD in women vs. men requires different assessment methods and diagnostic tools. We use extensive questionnaires that include questions about internal symptoms, emotional regulation, and social functioning. This allows us to identify female ADHD even in cases where symptoms have been missed previously.

Treatment at Amae Health is tailored to gender differences. For women, we consider the impact of the menstrual cycle on medication effectiveness and can adjust dosages during different phases of the cycle. Psychotherapeutic approaches also vary — men often benefit from strategies for managing impulsivity and aggression, while women tend to respond better to techniques for addressing perfectionism, anxiety, and self-esteem.

If you suspect that you or someone close to you has ADHD, contact the specialists at Amae Health. Our experience in identifying female ADHD has already helped hundreds of women receive the correct diagnosis and effective treatment, radically changing their quality of life. Don't let gender stereotypes deprive you of the opportunity to get the help you need — sign up for a consultation today.

Comparing Spravato vs ketamine infusion treatment means comparing two versions of the same idea: using ketamine's fast action on the brain's glutamate system to treat depression that standard antidepressants haven't relieved. The best comparison so far, a 2025 meta-analysis by Mayo Clinic researchers, found no statistically significant difference in how often the two lead to response or remission. What separates them is everything around the drug: FDA status, how it's given, how quickly it tends to work, what it costs, and who pays.

‍

So far, neither has been shown to be the better drug.

What Is Spravato (Esketamine)?

Esketamine vs ketamine comes down to chemistry. Standard ketamine is an equal mix of two mirror-image forms of the same molecule. Esketamine is one of those forms on its own, and Spravato is esketamine delivered as a nasal spray.

‍

The FDA first approved Spravato in 2019 for treatment-resistant depression, taken together with an oral antidepressant, as the Mayo Clinic review notes. A second approval, again paired with an oral antidepressant, covers depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior. And the most recent change came in January 2025, when the FDA added standalone use for treatment-resistant depression, as the current prescribing information shows.

‍

Every dose happens in a certified healthcare setting under the Spravato REMS, an FDA-required safety program. Each device delivers 28 mg, and a session uses two or three devices (56 or 84 mg), with a five-minute wait after each one. You're then monitored for at least two hours, and you can't drive again until the next day, once you've had a restful night's sleep. The label sets the early schedule: twice a week for weeks one through four, once a week for weeks five through eight, then weekly or every two weeks, adjusted to the least frequent dosing that maintains the response.

What Is Ketamine Infusion Therapy?

A ketamine infusion uses standard ketamine, both mirror-image forms together, delivered through an IV line. Ketamine has been FDA-approved as an anesthetic since 1970, but for depression, IV ketamine "remains an off-label treatment," in the Mayo Clinic review's words. Off-label prescribing is legal and common in medicine. It also means there is no FDA-approved depression regimen, so dosing schedules and safety protocols are set by each clinic.

‍

The most studied dose is 0.5 mg per kilogram of body weight, infused over about 40 minutes with continuous heart and blood pressure monitoring. A first course typically runs two to three infusions a week for about three to six treatments, followed by maintenance sessions on a schedule that varies from clinic to clinic.

Spravato vs Ketamine Infusion: Side-by-Side Comparison

Efficacy: What the Research Shows

The most complete head-to-head evidence is the 2025 Mayo Clinic meta-analysis in Therapeutic Advances in Psychopharmacology. The authors identified eight studies with 978 patients in total. Only one was a randomized trial, and it compared IV ketamine with an IV form of esketamine rather than the nasal spray, so the pooled comparison rests on observational studies of IV ketamine versus nasal esketamine.

‍

In those studies, the odds of response were 1.26 times higher with IV ketamine and the odds of remission 1.31 times higher, but neither difference was statistically significant. The authors concluded that the evidence suggests no significant difference in short-term efficacy, with a slight numerical trend favoring IV ketamine.

‍

Speed may be where the two differ. In one Mayo Clinic observational study included in the review, people reached remission after a median of two IV ketamine treatments, compared with seven nasal esketamine treatments. That's a real gap in lived experience. But it comes from observational data, where the people who choose or can access each treatment may differ in ways a study can't fully account for.

‍

So is Spravato better than ketamine infusions? On current evidence, neither has been shown to be. A randomized trial built to settle the question, called EQUIVALENCE, plans to assign 400 people to one treatment or the other for eight sessions over four weeks. Its protocol was published in 2026, and results are not yet available.

FDA Approval and Insurance Coverage

FDA approval changes who pays. Because Spravato has approved indications, insurers can write coverage criteria around it, and they typically require prior authorization and documentation of earlier antidepressant trials. Ketamine infusions for depression are off-label, so coverage is inconsistent, and many people pay out of pocket.

‍

The Spravato vs ketamine cost comparison has a twist. Economic modeling cited in the Mayo Clinic review found nasal esketamine unlikely to be cost-effective compared with IV ketamine from a health-system perspective. Yet an individual patient's out-of-pocket cost for Spravato may be lower, thanks to insurance coverage or manufacturer assistance. Published price estimates vary too widely by dose, frequency, and coverage to quote a single figure, so ask each provider and your insurer for the numbers that apply to you.

Side Effects and Safety Considerations

Because both drugs act on the same receptor, their side effects overlap. In Spravato's clinical trials, 48% to 61% of people developed sedation, and 61% to 84% experienced dissociative or perceptual changes, such as distortions of time or space, according to the prescribing information. Dizziness, nausea, vertigo, anxiety, and a temporary rise in blood pressure are also common, which is why blood pressure is rechecked about 40 minutes after dosing. IV ketamine produces the same family of effects, concentrated during and shortly after the infusion.

‍

Direct safety comparisons are limited. In one retrospective analysis included in the Mayo Clinic review, a rise in blood pressure during treatment occurred in 45% of IV ketamine patients versus 9.2% of nasal esketamine patients, and dissociative effects were also more frequent with IV ketamine, though they were described as transient. That is one retrospective study. It doesn't establish either drug as safer overall.

‍

Both drugs carry a potential for misuse, which shapes who is a candidate, and each has its own exclusions. Spravato, for example, isn't used in people with aneurysmal blood vessel disease, an arteriovenous malformation, or a history of bleeding in the brain.

What Influences the Choice Between Them

There isn't a universal right answer. A psychiatrist weighing the two usually considers:

‍

• Coverage and cost. Whether insurance will cover Spravato in your situation, and whether infusions are affordable out of pocket.
• How quickly relief is needed. Early data suggest infusions may reach remission in fewer sessions, which matters more when symptoms are severe.
• Medical history. Blood pressure, vascular conditions, and any history of substance misuse.
• Route. Some people would rather avoid an IV line. Others prefer an infusion that can be slowed or stopped.
• Logistics. Spravato means at least two hours in the clinic and no driving until the next day, twice a week at first. Infusions take about 40 minutes, plus recovery time that varies by clinic.
• Continuity. Whether you're already established with a psychiatrist or clinic that offers one of them.

‍

The choice belongs in a conversation with a psychiatrist who knows your treatment history, not in a ranking of favorites.

Making the Decision With a Psychiatrist

Spravato and ketamine infusions are tools for treatment-resistant depression, not a complete plan. They work alongside medication, therapy, and ongoing psychiatric care, and they sit among other options, including TMS therapy for depression that hasn't responded to medication. When depression brings thoughts of suicide, care for suicidal thoughts comes first.

‍

We don't offer Spravato at Amae. Our psychiatrists treat depression that hasn't responded to medication through our integrated care model, with therapy, medication management, and TMS, which we provide in Los Altos, San Mateo, and Los Angeles. Whether the question is Spravato vs ketamine infusion or something else entirely, talk through your options with an Amae psychiatrist, including ones we don't provide ourselves. For anyone in crisis right now, 988 is a call or text away.

Frequently Asked Questions

Is Spravato more effective than ketamine infusions?

Not on current evidence. A 2025 meta-analysis found no statistically significant difference in response or remission between IV ketamine and nasal esketamine, only a slight numerical trend favoring IV ketamine. Most of that evidence is observational, and a large randomized head-to-head trial is still underway.

Which works faster, Spravato or ketamine infusions?

IV ketamine may reach remission in fewer sessions. In one observational study, the median was two IV infusions versus seven nasal esketamine treatments. Because that finding comes from observational data rather than a randomized trial, treat it as preliminary.

Is Spravato safer than ketamine infusions?

Neither has been established as safer overall. The two share a similar side-effect profile because they act on the same receptor. One retrospective comparison found more blood pressure spikes and dissociation with IV ketamine, but a single study can't settle the question, and individual risk depends on your medical history.

Why is Spravato covered by insurance but ketamine infusions often aren't?

Spravato has FDA approval for treatment-resistant depression, which gives insurers defined criteria for covering it, usually with prior authorization. IV ketamine for depression is off-label, so coverage is inconsistent and infusions are often self-pay.

Can I switch between Spravato and ketamine infusions?

That's a clinical decision to make with a psychiatrist, based on how you've responded, the side effects you've had, your goals, and your coverage. It isn't something to change on your own.

How many sessions does each treatment typically require?

Spravato starts at twice a week for four weeks, then weekly, then weekly or every two weeks based on response. Ketamine infusions often begin with three to six sessions given two to three times a week, followed by maintenance on a schedule that varies by clinic.

‍

Citations

1. Elmosalamy A, Tarikogullari I, Patarroyo-Rodriguez L, et al. Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12615959/ (Tier 1)
2. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray prescribing information, revised January 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf (Tier 2)
3. Wilkinson ST, Prashad S, Dalthorp R, et al. Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: the EQUIVALENCE trial protocol. Contemporary Clinical Trials. 2026;164:108273. https://pubmed.ncbi.nlm.nih.gov/41780747/ (Tier 1, trial protocol)
4. 988 Suicide and Crisis Lifeline. https://988lifeline.org (Tier 2)

‍